To describe global patterns of insulin treatment and to assess the impact of patient, provider, health system and economic influences on treatment decisions for patients with insulintreated type 2 diabetes (T2D).
generally one of deteriorating glycaemic control, with many individuals requiring a stepwise intensification of pharmacotherapy to achieve and maintain blood glucose control. 6 Escalation of therapy is necessary for many patients, in particular those treated with insulin, to achieve desired glycaemic targets. 7, 8 To date, few studies have systematically quantified the interplay among patient, physician and healthcare system and the use of insulin therapy over time. Some studies have reported on barriers to insulin initiation and progression of therapies to maintain glycaemic control, indicating that implementation of guidelines for T2D treatment remains inconsistent in a real-world setting. 9, 10 The Translating
Research Into Action for Diabetes (TRIAD) study identified several factors from patient and physician perspectives that were associated with lack of insulin initiation among T2D patients with poorly controlled disease; however, this study included a single country and focused on insulin initiation rather than intensification. 9, 11 No study has yet compared these factors across diverse regional, geographical, economic and healthcare settings.
The objective of the Multinational Observational Study Assessing Insulin Use: Understanding the Challenges Associated with
Progression of Therapy (MOSA1c; NCT01400971) study was to describe the determinants of diabetes-related treatment changes in a prospective real-world cohort across a global population of insulintreated patients with T2D, and to describe the extent to which patient-specific glycaemic goals were achieved. 12, 13 The study was designed to elucidate the specific challenges and the patient, physician and healthcare system factors associated with progression from initial to more advanced insulin treatment regimens. As such, this article describes observed treatment changes and associated predictors, as well as haemoglobin A1c (HbA1c) levels and hypoglycaemia events reported in this global, insulin-treated population of patients with T2D.
| METHODS

| Study design
The MOSA1c study was a non-interventional, prospective cohort study in 18 countries; complete methods were reported previously. 12, 13 Patient enrolment started in 2011, with a 2-year follow-up for each patient; the study concluded in 2015. Data captured at the baseline visit included retrospective data up to 6 months prior to baseline. Prospective data were collected at 6, 12, 18 and 24 months, with a window of ± 3 months around each time point.
The study protocol, informed consent forms and other applicable documents were approved by local ethical review boards as required by local regulations. The study was conducted according to the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with good clinical practices and applicable laws and regulations of the country or countries where the study was conducted, as appropriate. All patients gave written informed consent before any study-specific procedure was conducted. 
| Study setting
| Data sources and collection
Details on the approach for enrolment of a representative sample that reflects the underlying population with T2D, using insulin type and physician practice type in each participating country, have been described. 12 
| Statistical analysis
The primary analysis was a complete case analysis, restricted to patients with complete treatment data for all five visits. Patients for whom data concerning non-treatment-related descriptive variables were missing were included in the complete case analysis. As a secondary analysis, multiple imputation was conducted for selected variables with missing values; ten imputed datasets were created, analyses were performed separately in each dataset, and were then combined.
Baseline patient characteristics were compared across country Multivariable logistic regression models examined baseline patient-, physician-and healthcare system-related factors associated with any change in insulin therapy and any change in glucose-lowering therapies.
Variables were selected from univariate logistic models for each candidate factor, retaining those significant at P < 0.05. As a sensitivity analysis, personal income relative to country-specific, per capita gross domestic product (GDP) was included in the regression model.
Among patients with complete HbA1c measurements at baseline and at least one follow-up visit, change in HbA1c levels from baseline to each follow-up visit was summarized by change in insulin therapy and country economic group. Additionally, the percentage of patients reporting any hypoglycaemic episode since the last visit was reported by changes in insulin therapy and country economic group.
3 | RESULTS
| Patient demographic and clinical characteristics
Baseline data were collected from a total of 4299 eligible patients from 192 sites; complete treatment data were available for 2528 patients (58.8%). Counts of patients enrolled per region are provided in Table S1 . The main reason for exclusion from analysis was missing treatment data from one or more visits.
Patients for whom complete treatment data were available repre- (Table S2 ).
| Physician-and patient-reported characteristics
A majority of individuals in the entire cohort (69%) received diabetes care from endocrine specialists and had public health insurance (55%) ( Table 1) . Fewer patients from high-income countries were treated by endocrinologists (56%) compared to their lower-middle and uppermiddle-income counterparts (79% and 75%, respectively; P < 0.001);
however, physicians in the high-income regions tended to be more experienced, having treated patients with T2D for a longer time. Most patients with public insurance resided in upper-middle (74%) and high-income (64%) countries, with only 18% of patients utilizing public insurance in the lower-middle-income country.
Physicians from the lower-middle-income region treated the high- respectful, and reported that their physicians explained test results. In contrast, patients from the lower-middle-income country reported a higher level of perceived discrimination from their physicians (median score, 1.5) compared to upper-middle and high-income regions (median score, 1.0 for each). Patients from upper-middle-income countries reported fewer elicited concerns and more hurried communication, but more patient-centred decision-making. When multiple imputation was conducted, results were similar to non-imputed results (Table S3 ).
| Predictors of treatment change over time
During the 2-year follow-up period, changes in treatment with either insulin-or non-insulin-based glucose-lowering therapies were made for 90.0% of patients in the overall cohort, with an inverse association between treatment change and country economic status (P < 0.001) (Figure 1 ).
Most treatment changes involved insulin, although more than 40% of patients experienced a change in non-insulin glucose-lowering therapies. Any change (increase, decrease or bidirectional) in insulin therapy was more common in lower-middle-income regions (94.8%).
Patients from lower-middle regions were also more likely to experience any change in glucose-lowering therapies (96.7%) compared to other economic regions. Changes in insulin dose, either increase (67%) or decrease (50%), were the most common change across the entire cohort and were more frequent in lower-middle economic regions (Table S4 ). Changes in dose were typically at least a 5% increase or decrease relative to the dose at the prior visit; only 1% of patients experienced dose changes less than 5% with no other change in treatment. The median total daily insulin dose at baseline was 30 units in lower-middle and high-income countries and 34 units in upper-middle-income countries; by the end of the follow-up period, median doses were approximately four units higher than baseline in all regions (Table S5) . Among patients experiencing a change in dose, the median change from baseline to the end of the follow-up period was eight units for lower-middle and high-income countries and 10 units for Logistic regression models examining predictors of insulin changes at any time during follow-up, overall and by country economic group. CI, confidence interval; HbA1c, glycated haemoglobin; IPC, interpersonal process of care; OR, odds ratio using multiple imputation ( Figure S1 ) and predictors of change in any glucose-lowering therapy ( Figure S2) were generally similar to those in the primary analysis. The sensitivity analysis, adding personal income relative to country economic status, resulted in no change to the findings of the primary model. The major global diabetes treatment guidelines recommend setting personalized HbA1c target levels and modifying therapy if targets are not achieved within 3-6 months. 7, 23 Achieving and maintaining glycaemic control and assuring timely and appropriate adjustments in therapy for insulin-treated T2D patients remain significant clinical challenges. 7, 9, 11, 24, 25 Although the MOSA1c study was not designed to examine the impact of treatment changes on glycaemic control, the observed trend of relatively stable but not improved glycemic control, despite frequent treatment changes, may indicate that more targeted and more effective changes in therapy for T2D patients are necessary on a global scale. Thus, proper education of healthcare providers concerning effective approaches to patient management is important.
| Change in HbA1c levels and hypoglycaemic events
Patients and physicians should be provided with specific point-of-care information concerning treatment options and titration. Further educational opportunities and simulation exercises for tailored treatment approaches should be offered, so that healthcare providers can be better informed when making treatment decisions for individual patients.
Limitations of this study include its observational nature. The study protocol did not specify treatment prescribing or monitoring measures for patients, and data on variables of interest were missing for many patients; however, analyses of imputed data provided results similar to those of the complete case analysis. Changes in treatment and achievement of HbA1c targets were examined in a FIGURE 4 Percentage of patients with reported hypoglycaemic episodes since last visit, by insulin-related treatment change snapshot view across a 2-year period and do not reflect the continuity of treatment changes and HbA1c levels. Still, these data reflect real-world patterns of prescribing behaviours and glycaemic control, and they include an array of patient-reported factors relevant to physician management of insulin-treated T2D patients. Caution is needed in interpreting data across economic regions because of the heterogeneous socio-economic gradient for diabetes in developed vs developing countries. [26] [27] [28] [29] [30] [31] However, recent studies have shown that differences in the prevalence of diabetes according to country income group persist after adjusting for socio-economic status, and the socio-economic gradient in developing countries is reversing to become similar to their developed counterparts. [32] [33] [34] [35] [36] [37] Furthermore, the objective of this study was not to understand the impact of changes in treatment on HbA1c levels; future studies should address this question at a multinational level.
The data presented here are the first to longitudinally demon- 
